Insmed Incorporated , a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, presented 11 ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately ...

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online ...

Anaphylactic shock to tocilizumab was observed in one patient ... interleukin-6 with tocilizumab is effective in patients with adult-onset Still’s disease refractory to glucocorticoid therapy on ...

New research suggests classical biomarkers cannot discriminate between refractory and non-refractory rheumatoid arthritis. Novel targeted therapies have made a significant impact on the treatment ...

While some mild allergic reactions may resolve on their own, others, especially severe ones like anaphylaxis, require urgent medical attention. These can affect the body in several ways ...

The diagnosis of anaphylaxis can be tricky, especially in the absence of known triggers and when other conditions, such as urticaria and asthma, mimic aspects of the reaction. Biomarkers can help ...

A stinging ant species that can cause anaphylaxis in humans and has been found in the U.S. for 90 years is getting renewed attention. The Asian needle ant is native to Asia, given its name ...

An oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain alive and progression-free for more than 5 years after a single CARVYKTI® ...

Long-term data from the CARTITUDE-1 study evaluating CARVYKTI® in patients with heavily pretreated relapsed or refractory multiple myeloma who historically had an expected median progression-free ...